Myeloid neoplasms are a group of diseases characterized by a wide range of mutations across a large number of genes, including oncogenes and tumor suppressor genes. Genes commonly mutated in myeloid neoplasms include CALR and CEBPA for acute myeloid leukemia (AML) and TP53 or RB1 for chronic myeloid leukemia (CLL). These mutations are relevant for tumor classification and require extensive investigation to understand disease development and progression.

Rapid detection of mutations associated with myeloid neoplasms involves the use of targeted next-generation sequencing (NGS) panels comprising key genes commonly mutated in myeloid neoplasms. However, challenges such as low allele frequency of variants, high GC content and low enrichment of target DNA can complicate NGS results and analysis.

Choosing the right targeted NGS panel can make all the difference. Join our webinar where we’ll introduce you to our QIAseq Targeted DNA Pro Panels – a complete Sample to Insight NGS solution for analyzing myeloid neoplasms.